Ugo Nocentini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1170642/publications.pdf

Version: 2024-02-01

68	3,832	236833	133188
papers	citations	25 h-index	59 g-index

76	76	76	4844
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Mental Deterioration Battery: Normative Data, Diagnostic Reliability and Qualitative Analyses of Cognitive Impairment. European Neurology, 1996, 36, 378-384.	0.6	1,099
2	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
3	Patterns of dissociation in comprehension and production of nouns and verbs. Aphasiology, 1988, 2, 351-358.	1.4	261
4	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	4.9	238
5	Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. Journal of Neurology, 2004, 251, 1208-1214.	1.8	142
6	The role played by the right hemisphere in the organization of complex textual structures. Brain and Language, 2005, 93, 46-54.	0.8	121
7	Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 77-87.	1.4	119
8	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	0.8	99
9	Neuropsychological, medical and rehabilitative management of persons with multiple sclerosis. NeuroRehabilitation, 2011, 29, 197-219.	0.5	77
10	Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. NeuroReport, 1999, 10, 399-402.	0.6	61
11	Diffusion of water in large demyelinating lesions: a follow-up study. Neuroradiology, 2002, 44, 764-767.	1.1	56
12	The Symbol Digit Modalities Test - Oral version: Italian normative data. Functional Neurology, 2006, 21, 93-6.	1.3	56
13	Patterns of Cognitive Impairment in Secondary Progressive Stable Phase of Multiple Sclerosis: Correlations with MRI Findings. European Neurology, 2001, 45, 11-18.	0.6	50
14	Functional connectivity changes within specific networks parallel the clinical evolution of multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1050-1057.	1.4	47
15	Training on the International Classification of Functioning, Disability and Health (ICF): the ICFâ€“DIN Basic and the ICFâ€“DIN Advanced Course developed by the Disability Italian Network. Journal of Headache and Pain, 2005, 6, 159-164.	2.5	43
16	Disruption of neurite morphology parallels MS progression. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e502.	3.1	43
17	Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis. Brain Imaging and Behavior, 2014, 8, 378-386.	1.1	41
18	Role of inflammation and apoptosis in multiple sclerosis: Comparative analysis between the periphery and the central nervous system. Journal of Neuroimmunology, 2015, 287, 80-87.	1.1	41

#	Article	IF	Citations
19	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. Journal of Neurology, 2003, 250, 1094-1098.	1.8	40
20	Implicit Memory in Parkinsonian Patients: Evidence for Deficient Skill Learning. European Neurology, 1996, 36, 154-159.	0.6	39
21	Coefficient D(av) is more sensitive than fractional anisotropy in monitoring progression of irreversible tissue damage in focal nonactive multiple sclerosis lesions. American Journal of Neuroradiology, 2003, 24, 663-70.	1.2	37
22	Anatomical brain connectivity can assess cognitive dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1161-1168.	1.4	33
23	Validation of the World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 448-456.	1.4	33
24	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	0.8	31
25	Autoantibodies in Multiple Sclerosis Patients Before and During IFN-Î²1b Treatment: Are They Correlated with the Occurrence of Autoimmune Diseases?. Journal of Interferon and Cytokine Research, 2002, 22, 245-255.	0.5	28
26	An Italian experience in the ICF implementation in rehabilitation: Preliminary theoretical and practical considerations. Disability and Rehabilitation, 2008, 30, 1146-1152.	0.9	25
27	Interhemispheric transfer time in a patient with a partial lesion of the corpus callosum. NeuroReport, 2001, 12, 1469-1472.	0.6	22
28	Investigation of quantitative magnetisation transfer parameters of lesions and normal appearing white matter in multiple sclerosis. NMR in Biomedicine, 2009, 22, 646-653.	1.6	19
29	An open-label pilot study of the use of rivastigmine to promote functional recovery in patients with unilateral spatial neglect due to first ischemic stroke. Functional Neurology, 2010, 25, 195-200.	1.3	19
30	An exploration of anger phenomenology in multiple sclerosis. European Journal of Neurology, 2009, 16, 1312-1317.	1.7	16
31	Cognitive Functions in Adult Down's Syndrome. International Journal of Neuroscience, 1990, 54, 221-230.	0.8	15
32	Occupational stress and personality traits in multiple sclerosis: A preliminary study. Multiple Sclerosis and Related Disorders, 2015, 4, 315-319.	0.9	15
33	Regression-Based Norms for the Brief Visuospatial Memory Test-Revised in Italian population and application in MS patients. Clinical Neuropsychologist, 2016, 30, 1469-1478.	1.5	13
34	Parageusia: An Unusual Presentation of Multiple Sclerosis. European Neurology, 2004, 51, 123-124.	0.6	12
35	Multiparametric MR investigation of the motor pyramidal system in patients with â€˜truly benignâ€™ multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 178-188.	1.4	12
36	Dual-Task Performance in Multiple Sclerosisâ€™ Patients: Cerebellum Matters?. Archives of Clinical Neuropsychology, 2021, 36, 517-526.	0.3	12

#	Article	IF	Citations
37	Adverse working events in patients with multiple sclerosis. Neurological Sciences, 2017, 38, 349-352.	0.9	11
38	The effects of left- versus right-hemisphere lesions on the sensitivity to intra- and interconceptual semantic relationships. Neuropsychologia, 2001, 39, 443-451.	0.7	10
39	Infratentorial lesion volume correlates with sensory functional system in multiple sclerosis patients: a 3.0-Tesla MRI study. Radiologia Medica, 2010, 115, 115-124.	4.7	9
40	The nature of lexical-semantic impairment in Alzheimer's disease. Journal of Neurolinguistics, 1989, 4, 449-460.	0.5	8
41	Selective proper name anomia in a patient with asymmetric cortical degeneration. European Journal of Neurology, 1998, 5, 417-422.	1.7	8
42	Neuropsychiatric Dysfunction in Multiple Sclerosis. , 2012, , .		8
43	The California Verbal Learning Test- II: Normative Data for Two Italian Alternative Forms. Clinical Neuropsychologist, 2014, 28, 42-54.	1.5	8
44	Age-Related Evolution of the Contribution of the Right Hemisphere to Language: Absence of Evidence. International Journal of Neuroscience, 1999, 99, 59-67.	0.8	7
45	Defective Fas ligand production in lymphocytes from MS patients. NeuroReport, 2001, 12, 4113-4116.	0.6	7
46	Domestic accidents and multiple sclerosis: an exploratory study of occurrence and possible causes. Disability and Rehabilitation, 2014, 36, 2205-2209.	0.9	7
47	The Italian validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the application of the Cognitive Impairment Index scoring procedure in MS patients. Neurological Sciences, 2018, 39, 1237-1244.	0.9	7
48	A Preliminary Investigation of Abnormal Personality Traits in MS Using the MCMI-III. Applied Neuropsychology Adult, 2015, 22, 452-458.	0.7	6
49	Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989, 13, S47-S59.	2.5	5
50	Semantic field integrity and naming ability in anomic patients. Aphasiology, 1989, 3, 423-434.	1.4	4
51	Clinical assessment and therapy for depression. Neurological Sciences, 2006, 27, s341-s343.	0.9	4
52	Assessing measurement invariance of MSQOL-54 across Italian and English versions. Quality of Life Research, 2020, 29, 783-791.	1.5	4
53	A more in-depth interpretation of MMPI-2 in MS patients by using Harris and Lingoes subscales. Applied Neuropsychology Adult, 2017, 24, 439-445.	0.7	2
54	Can personality traits influence occupational stress in multiple sclerosis patients? A one-year longitudinal study. Applied Neuropsychology Adult, 2020, 27, 390-392.	0.7	2

#	Article	IF	Citations
55	An Italian Neurorehabilitation Hospital Facing the SARS-CoV-2 Pandemic: Data From 1207 Patients and Workers. Frontiers in Neurology, 2020, 11, 584317.	1.1	2
56	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. Health and Quality of Life Outcomes, 2021, 19, 224.	1.0	2
57	Anxiety and Multiple Sclerosis. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 39-63.	0.3	2
58	Cognitive Dysfunctions in Multiple Sclerosis. , 2013, , 133-153.		1
59	Assessing clinical correlates of self-rated disability in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731559242.	0.5	1
60	Study Protocol: Strategies and Techniques for the Rehabilitation of Cognitive and Motor Deficits in Patients with Multiple Sclerosis. NeuroSci, 2022, 3, 395-407.	0.4	1
61	Comparison of the effectiveness of motor and cognitive rehabilitation alone compared to the combination of the two in patients with multiple sclerosis. Journal of the Neurological Sciences, 2021, 429, 118566.	0.3	0
62	I deficit cognitivi nella sclerosi multipla. , 2011, , 123-144.		0
63	Aspetti clinici generali. , 2011, , 3-31.		0
64	Clinical Presentation. , 2013, , 11-19.		0
65	Assessment Instruments. , 2013, , 37-41.		0
66	Emotions and Multiple Sclerosis. , 2013, , 127-130.		0
67	Etiopathogenesis. , 2013, , 21-25.		0
68	Can we offer more for cognitive impairment in patients with chronic hepatitis C?. Arquivos De Neuro-Psiquiatria, 2020, 78, 319-320.	0.3	0